Developer docs
API playgroundTry for free, no card

Search company profiles

Siloam Vision

Full company profile

uuid006a5th

Namestring
Siloam Vision
Legal namestring
Siloam Vision Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Siloam Vision is a venture-backed medical-device and software company developing AI-assisted ophthalmic imaging systems focused primarily on retinopathy of prematurity (ROP), the leading cause of childhood blindness. Its integrated product portfolio combines two proprietary hardware platforms — the iCam Scanning Laser Ophthalmoscope (SLO) camera and the iCam-OCT Optical Coherence Tomography system (featuring a 200-degree contact field of view, 145-degree non-contact field of view, 1060nm swept-source laser, and acquisition speeds up to 1,000 frames per second) — with two software platforms: iTelegen, a telemedicine system for managing ROP exam scheduling, automated reminders, and remote image review, and iTelegen+, which layers in two proprietary AI algorithms (iROP-Dx for automated detection of more-than-mild ROP and iROP-Assist for clinician-assistive analysis) that were recognized with the FDA's first Breakthrough Device Designation for AI-based ROP screening.

The company targets two end markets: neonatal intensive care units (NICUs) in hospitals serving premature infants at risk of ROP, and broader ophthalmology practices needing ultra-wide-field retinal imaging across all age groups. Its go-to-market is enterprise field sales to hospitals and healthcare systems, supplemented by a flagship strategic partnership with Orbis International for humanitarian deployment in underserved regions; an active AI-assisted ROP screening program has been running in Mongolia since 2023 and is planned to extend to Bangladesh.

Siloam Vision generates revenue through a mix of hardware sales (iCam, iCam-OCT), software licensing (iTelegen, iTelegen+), and non-dilutive grant funding (NIH, SBIR), with a parallel dilutive SAFE-note funding track. It is a Delaware-incorporated, Portland/Oregon-headquartered private company with 1–10 employees, currently in a pre-commercial / investigational-use phase pending full FDA clearance.

Short descriptiontext

Siloam Vision is a Portland-based medical-device and software company developing AI-assisted retinal imaging and telemedicine systems, primarily to screen premature infants for retinopathy of prematurity (ROP) in hospital NICUs and underserved global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLake Oswego, United States
HQ citystring
Lake Oswego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic imaging devices, retinopathy screening software, AI retinal diagnostics, neonatal vision assessment, telemedicine eye care
Industry2 codes
PRIMARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Medical Imaging Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1SAFE Securities Offering
TypeLicensing Royalties
Description

Exempt securities offering under Rule 506(c) raising capital through Simple Agreements for Future Equity. Minimum investment of $50,000 from outside investors.

sec.gov
2Medical Device Hardware Sales
TypeHardware Sales
Description

Sale of proprietary imaging devices including iCam SLO cameras and iCam-OCT systems to healthcare providers and hospitals.

siloamvision.com
3Software Platform Licensing
TypeSubscription Recurring
Description

Licensing of iTelegen and iTelegen+ software platforms for ROP management and AI-assisted diagnosis to healthcare institutions.

siloamvision.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1SAFE Investment
ModelOtherBilling cadencePay-as-you-go
Notes

Minimum investment of $50,000 from outside investors. $700,000 total offering value with $350,000 already sold to 2 investors as of January 2026.

sec.gov
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1iTelegen
Description

Intuitive software designed for collaborative care that streamlines ROP exam management, scheduling, and remote image review.

siloamvision.com
+3 more records
Core offering1 text field

Siloam Vision develops and sells an integrated portfolio of ophthalmic imaging hardware and AI-powered software for vision assessment and therapy. The iTelegen and iTelegen+ software platforms manage retinopathy of prematurity (ROP) screening, while the patented iCam handheld SLO camera and iCam-OCT system capture high-resolution retinal images. Together, these products enable AI-assisted diagnosis and remote image review for hospitals, neonatal care units, and eye care professionals, particularly in underserved regions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results within seconds compared to days previously
+2 more records
Product overview1 text field

Siloam Vision offers an integrated eye care technology portfolio comprising both software platforms and hardware imaging devices. The iTelegen™ software platform serves as the core ROP management system, with iTelegen+™ adding AI-powered diagnostic assistance through iROP-Dx and iROP-Assist algorithms. These software platforms integrate with the iCam™ handheld SLO camera and iCam-OCT™ advanced OCT system, which capture retinal images for analysis. Together, these products form a comprehensive solution for preventing blindness through AI-assisted screening and diagnosis of retinopathy of prematurity and other eye conditions.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Strategic partnership with Orbis International to scale ROP screening solution globally. Joint initiative conducted world's first AI-assisted ROP screening program in Mongolia. Program expanding to Bangladesh with screenings scheduled to begin in Dhaka. Includes training for doctors in remote provinces using smartphone-attached retinal cameras.

2Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Harvard Medical School as part of the iROP consortium for imaging and informatics research in retinopathy of prematurity since 2010.

siloamvision.com
3Oregon Health & Science University (OHSU)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with OHSU where founders Dr. Pete Campbell and Dr. Paul Chan are faculty members. OHSU research coverage of company's technology development including FDA breakthrough designation.

siloamvision.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Orbis International is Siloam Vision's flagship humanitarian distribution partner running the Mongolia and Bangladesh ROP programs — not a competitor, but a closely adjacent ecosystem participant whose priorities materially shape Siloam's go-to-market.

TypeDirect peer
Description

Phoenix Technology Group (now part of Leica Microsystems) makes the RetCam wide-field pediatric retinal imaging system used in NICUs for ROP screening — a direct competitor to Siloam's iCam/iCam-OCT in the same clinical workflow.

TypeDirect peer
Description

Digital Diagnostics commercializes IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy — a comparable autonomous AI diagnostic regulatory and commercial pathway to Siloam's iROP-Assist AI.

TypeBroad incumbent
Description

Heidelberg Engineering manufactures the SPECTRALIS OCT and HRA imaging platforms widely used in retina practices — a broad incumbent with overlapping OCT/SLO capabilities that compete against the iCam-OCT system.

TypeBroad incumbent
Description

Optos, owned by Nikon, is the dominant ultra-widefield retinal imaging incumbent (Panoramic 200, California) used in ophthalmology clinics worldwide — a broader commercial incumbent competing with Siloam's iCam SLO ultra-widefield system.

TypeDirect peer
Description

Eyenuk's EyeArt system is an FDA-cleared AI platform for autonomous diabetic retinopathy detection from retinal images, directly comparable to Siloam's iTelegen+/iROP-Assist AI for automated disease screening in eye care.

TypeEmerging player
Description

iCare manufactures handheld ophthalmic diagnostic devices (tonometry, retinal imaging) used in primary care and emerging markets — comparable in form factor and portability philosophy to Siloam's handheld iCam SLO.

TypeDirect peer
Description

AEYE Health develops FDA-cleared AI for autonomous retinal disease screening from fundus images, including diabetic retinopathy, and is moving into adjacent retinal indications that overlap directly with Siloam's AI-ROP workflow.

TypeEmerging player
Description

RetinAI builds AI-based image analysis platforms for retinal disease management (Discovery, IOL prediction) — an emerging peer in ophthalmic AI workflow software that overlaps with iTelegen+ platform capabilities.

10Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec offers the CIRRUS HD-OCT and PLEX Elite OCT systems with broad clinical retinal imaging adoption — a large incumbent whose OCT portfolio directly overlaps with Siloam's iCam-OCT positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Siloam Vision

Ophthalmic Medical Imaging Devicessiloamvision.com

Siloam Vision is a Portland-based medical-device and software company developing AI-assisted retinal imaging and telemedicine systems, primarily to screen premature infants for retinopathy of prematurity (ROP) in hospital NICUs and underserved global markets.

What Siloam Vision does

Siloam Vision is a venture-backed medical-device and software company developing AI-assisted ophthalmic imaging systems focused primarily on retinopathy of prematurity (ROP), the leading cause of childhood blindness. Its integrated product portfolio combines two proprietary hardware platforms — the iCam Scanning Laser Ophthalmoscope (SLO) camera and the iCam-OCT Optical Coherence Tomography system (featuring a 200-degree contact field of view, 145-degree non-contact field of view, 1060nm swept-source laser, and acquisition speeds up to 1,000 frames per second) — with two software platforms: iTelegen, a telemedicine system for managing ROP exam scheduling, automated reminders, and remote image review, and iTelegen+, which layers in two proprietary AI algorithms (iROP-Dx for automated detection of more-than-mild ROP and iROP-Assist for clinician-assistive analysis) that were recognized with the FDA's first Breakthrough Device Designation for AI-based ROP screening.

The company targets two end markets: neonatal intensive care units (NICUs) in hospitals serving premature infants at risk of ROP, and broader ophthalmology practices needing ultra-wide-field retinal imaging across all age groups. Its go-to-market is enterprise field sales to hospitals and healthcare systems, supplemented by a flagship strategic partnership with Orbis International for humanitarian deployment in underserved regions; an active AI-assisted ROP screening program has been running in Mongolia since 2023 and is planned to extend to Bangladesh.

Siloam Vision generates revenue through a mix of hardware sales (iCam, iCam-OCT), software licensing (iTelegen, iTelegen+), and non-dilutive grant funding (NIH, SBIR), with a parallel dilutive SAFE-note funding track. It is a Delaware-incorporated, Portland/Oregon-headquartered private company with 1–10 employees, currently in a pre-commercial / investigational-use phase pending full FDA clearance.

Siloam Vision firmographics

Firmographics
Name
Siloam Vision
Legal name
Siloam Vision Inc.
Website
https://siloamvision.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Siloam Vision is a Portland-based medical-device and software company developing AI-assisted retinal imaging and telemedicine systems, primarily to screen premature infants for retinopathy of prematurity (ROP) in hospital NICUs and underserved global markets.
Ownership category
akta.pro rank

Siloam Vision industry classification

Industry
Product category
Ophthalmic Medical Imaging Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic imaging devices
  • Retinopathy screening software
  • AI retinal diagnostics
  • Neonatal vision assessment
  • Telemedicine eye care

Where Siloam Vision is headquartered

Location

Headquarters

HQ city
Lake Oswego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Siloam Vision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. SAFE Securities Offering: Exempt securities offering under Rule 506(c) raising capital through Simple Agreements for Future Equity. Minimum investment of $50,000 from outside investors.
  2. Medical Device Hardware Sales: Sale of proprietary imaging devices including iCam SLO cameras and iCam-OCT systems to healthcare providers and hospitals.
  3. Software Platform Licensing: Licensing of iTelegen and iTelegen+ software platforms for ROP management and AI-assisted diagnosis to healthcare institutions.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSAFE Investment

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Siloam Vision product offering

Product offering

Core offering

Siloam Vision develops and sells an integrated portfolio of ophthalmic imaging hardware and AI-powered software for vision assessment and therapy. The iTelegen and iTelegen+ software platforms manage retinopathy of prematurity (ROP) screening, while the patented iCam handheld SLO camera and iCam-OCT system capture high-resolution retinal images. Together, these products enable AI-assisted diagnosis and remote image review for hospitals, neonatal care units, and eye care professionals, particularly in underserved regions.

Product overview

Siloam Vision offers an integrated eye care technology portfolio comprising both software platforms and hardware imaging devices. The iTelegen™ software platform serves as the core ROP management system, with iTelegen+™ adding AI-powered diagnostic assistance through iROP-Dx and iROP-Assist algorithms. These software platforms integrate with the iCam™ handheld SLO camera and iCam-OCT™ advanced OCT system, which capture retinal images for analysis. Together, these products form a comprehensive solution for preventing blindness through AI-assisted screening and diagnosis of retinopathy of prematurity and other eye conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • iTelegen: Intuitive software designed for collaborative care that streamlines ROP exam management, scheduling, and remote image review.
  • iTelegen+
  • iCam
  • iCam-OCT

Quantifiable outcome

  • Results within seconds compared to days previously
  • +2 more outcomes

Companies that use Siloam Vision

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Siloam Vision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Siloam Vision partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Orbis InternationalflagshipStrategic or Co-development Partner · 21 September 2023Strategic partnership with Orbis International to scale ROP screening solution globally. Joint initiative conducted world's first AI-assisted ROP screening program in Mongolia. Program expanding to Bangladesh with screenings scheduled to begin in Dhaka. Includes training for doctors in remote provinces using smartphone-attached retinal cameras.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerResearch collaboration with Harvard Medical School as part of the iROP consortium for imaging and informatics research in retinopathy of prematurity since 2010.
  • Oregon Health & Science University (OHSU)coreStrategic or Co-development PartnerResearch collaboration with OHSU where founders Dr. Pete Campbell and Dr. Paul Chan are faculty members. OHSU research coverage of company's technology development including FDA breakthrough designation.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Siloam Vision competitors and assessment

Company assessment

Others

  • Orbis International: Orbis International is Siloam Vision's flagship humanitarian distribution partner running the Mongolia and Bangladesh ROP programs — not a competitor, but a closely adjacent ecosystem participant whose priorities materially shape Siloam's go-to-market.

Direct peers

  • Phoenix Technology Group: Phoenix Technology Group (now part of Leica Microsystems) makes the RetCam wide-field pediatric retinal imaging system used in NICUs for ROP screening — a direct competitor to Siloam's iCam/iCam-OCT in the same clinical workflow.
  • Digital Diagnostics (IDx): Digital Diagnostics commercializes IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy — a comparable autonomous AI diagnostic regulatory and commercial pathway to Siloam's iROP-Assist AI.
  • Eyenuk: Eyenuk's EyeArt system is an FDA-cleared AI platform for autonomous diabetic retinopathy detection from retinal images, directly comparable to Siloam's iTelegen+/iROP-Assist AI for automated disease screening in eye care.
  • AEYE Health: AEYE Health develops FDA-cleared AI for autonomous retinal disease screening from fundus images, including diabetic retinopathy, and is moving into adjacent retinal indications that overlap directly with Siloam's AI-ROP workflow.

Broad incumbents

  • Heidelberg Engineering: Heidelberg Engineering manufactures the SPECTRALIS OCT and HRA imaging platforms widely used in retina practices — a broad incumbent with overlapping OCT/SLO capabilities that compete against the iCam-OCT system.
  • Optos (Nikon): Optos, owned by Nikon, is the dominant ultra-widefield retinal imaging incumbent (Panoramic 200, California) used in ophthalmology clinics worldwide — a broader commercial incumbent competing with Siloam's iCam SLO ultra-widefield system.
  • Carl Zeiss Meditec: Carl Zeiss Meditec offers the CIRRUS HD-OCT and PLEX Elite OCT systems with broad clinical retinal imaging adoption — a large incumbent whose OCT portfolio directly overlaps with Siloam's iCam-OCT positioning.

Emerging players

  • iCare (Icare Finland Oy): iCare manufactures handheld ophthalmic diagnostic devices (tonometry, retinal imaging) used in primary care and emerging markets — comparable in form factor and portability philosophy to Siloam's handheld iCam SLO.
  • RetinAI Medical: RetinAI builds AI-based image analysis platforms for retinal disease management (Discovery, IOL prediction) — an emerging peer in ophthalmic AI workflow software that overlaps with iTelegen+ platform capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Siloam Vision social profiles

Digital presence

Siloam Vision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Siloam Vision leadership team

Management profile

Number of profiles

Profiles10 records

Siloam Vision funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Siloam Vision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Siloam Vision

What does Siloam Vision do?

Siloam Vision develops and sells an integrated portfolio of ophthalmic imaging hardware and AI-powered software for vision assessment and therapy. The iTelegen and iTelegen+ software platforms manage retinopathy of prematurity (ROP) screening, while the patented iCam handheld SLO camera and iCam-OCT system capture high-resolution retinal images. Together, these products enable AI-assisted diagnosis and remote image review for hospitals, neonatal care units, and eye care professionals, particularly in underserved regions.

Is Siloam Vision a public or private company?

Siloam Vision is a private company. It is classified as venture growth investor backed and is currently operating.

When was Siloam Vision founded?

Siloam Vision was founded in 2010. It employs 1 to 10 people.

Where is Siloam Vision based?

Siloam Vision is headquartered in Lake Oswego, United States, in the North America region.

How does Siloam Vision make money?

Three revenue lines are on record. SAFE Securities Offering is the primary driver. The others are medical Device Hardware Sales and software Platform Licensing.

Who are Siloam Vision's main competitors?

Orbis International is listed as an others. Direct peers are Phoenix Technology Group, Digital Diagnostics (IDx), Eyenuk and AEYE Health. Broad incumbents are Heidelberg Engineering, Optos (Nikon) and Carl Zeiss Meditec. Emerging players are iCare (Icare Finland Oy) and RetinAI Medical.

Does Siloam Vision have an API?

No public API is recorded for Siloam Vision.

What industry is Siloam Vision in?

Siloam Vision's product category is Ophthalmic Medical Imaging Devices. Its primary akta.pro industry code is HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers, with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWorld First: Babies Screened for Blindness Using Artificial IntelligenceOrbis International and Siloam Vision conducted the world's first AI-assisted retinopathy of prematurity screening on premature infants at the National Center for Maternal and Child Health in Ulaanbaatar, Mongolia, using Siloam's FDA breakthrough-designated iTelegen telemedicine platform. The program enables results to be generated within seconds compared to days previously, addressing a critical gap in countries with limited ophthalmology specialists where an estimated 32,000 pre-term babies worldwide become permanently blind from ROP annually. The initiative, which has already conducted over 270 exams on more than 170 newborn babies since its 2023 launch, is being expanded to Bangladesh with screenings scheduled to begin in Dhaka this month.MorningstarWorld First: Babies Screened for Blindness Using Artificial IntelligenceOrbis International and Siloam Vision achieved a world first by using AI to screen premature babies for retinopathy of prematurity—the leading cause of childhood blindness globally—at the National Center for Maternal and Child Health in Ulaanbaatar, Mongolia, on May 14, 2026. Siloam Vision's AI system, the first to receive FDA breakthrough status, integrates with the iTelegen telemedicine platform to provide faster, more reliable detection in settings where specialist ophthalmologists are scarce. The program also includes training for doctors in remote provinces using smartphone-attached retinal cameras, and is being expanded to Bangladesh with screening scheduled to begin in Dhaka this month.SecSEC FORM DSiloam Vision, Inc., a Delaware-registered health care technology company based in Portland, Oregon, filed a Form D notice with the SEC on January 28, 2026, for an exempt securities offering of Simple Agreements for Future Equity (SAFE) under Rule 506(c). The offering has a total value of $700,000, with $350,000 already sold to 2 investors as of the first sale on January 26, 2026, leaving $350,000 remaining. The minimum investment accepted from outside investors is $50,000, and the company has elected not to disclose its revenue range.SecSEC FORM DSiloam Vision, Inc. filed a Form D notice with the SEC on October 1, 2025, for an exempt offering of securities under Rule 506(c), raising $745,000 through Simple Agreements for Future Equity (SAFE). The offering, with a minimum investment of $45,000 from outside investors, attracted 8 investors and was fully subscribed with no remaining amount to be sold. Approximately $170,000 of the proceeds are estimated for payments to the company's executive officers and directors, including CEO John Peter Campbell.SecSEC FORM DSiloam Vision, Inc., a Delaware-incorporated health care technology company based in Portland, Oregon, filed a Form D notice with the SEC on October 1, 2025, reporting an exempt offering of convertible promissory notes totaling $500,000 USD that was fully sold as of the first sale date of May 12, 2022.SecSEC FORM DSiloam Vision, Inc., a Delaware corporation based in Portland, Oregon, filed a Form D notice with the SEC on October 1, 2025, reporting a completed exempt securities offering of $1,085,000 under Rule 506(b). The offering, structured as Simple Agreements for Future Equity (SAFE), attracted 8 investors with a minimum investment of $60,000. Approximately $45,000 of the proceeds are designated for estimated payments to the company's executive officers.SecSEC FORM DSiloam Vision, Inc. filed a Form D notice with the SEC notifying regulators of an exempt offering of securities under Rule 506(b), raising $550,000 through Simple Agreements for Future Equity (SAFE) with a minimum investment of $50,000 from five investors. The company, incorporated in Delaware and headquartered in Portland, Oregon, operates in the healthcare sector and disclosed that $157,396 of proceeds would be allocated for payments to executive officers. This is a routine regulatory filing required when companies conduct exempt securities offerings under Regulation D.PR NewswireEye Care Organizations Unite to Save Sight of Premature Infants Using Artificial IntelligenceOrbis International and Siloam Vision announced a partnership to use Siloam's AI platform for diagnosing retinopathy of prematurity in premature infants. The system has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this in nearly a decade.